Human CD34+-derived plasmacytoid dendritic cells as surrogates for primary pDCs and potential cancer immunotherapy
This study highlights CB-pDCs as surrogates for primary pDCs to investigate their biology and for their potential use as cell therapy in cancer.
Authors
- Giovanna Fiore
- Llucia Albertí Servera (ORCID: https://orcid.org/0000-0002-4168-060X)
- Sina Nassiri (ORCID: https://orcid.org/0000-0003-1274-8123)
- Manuela Gies
- Steffen Dettling
- Anne Krug (ORCID: https://orcid.org/0000-0002-9556-7207)
- Kerstin Paetzold
- Meher Majety (ORCID: https://orcid.org/0000-0002-1936-2277)
- Martina Antoniolli
- Stephan Schmeing (ORCID: https://orcid.org/0000-0001-9735-2931)
- Sabine Hoves (ORCID: https://orcid.org/0000-0002-4953-7234)
- Bhavesh Soni (ORCID: https://orcid.org/0009-0002-1093-9452)
- Monika Wolf
- Wolfgang Weckwarth
- Jakob Rosenhauer
Institutions
- Roche (Switzerland) (CH)
- Roche Pharma AG (Germany) (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-11-07
- DOI
- https://doi.org/10.3389/fimmu.2024.1433119
- Citations
- 1
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.24